These include the use of selective estrogen receptor modulators (SERMs) in healthy women at high risk of developing breast cancer due to a family history and other personal risk factors, or aspirin for colorectal cancer prevention in individuals with Lynch syndrome, or people aged 50–59 years, who are also at high risk for cardiovascular disease. Here, ESR1 is linked to breast cancer.